ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION [SIN15302P]
Active ingredients: CHROMIC CHLORIDE HEXAHYDRATE | COPPER CHLORIDE DIHYDRATE | FERRIC CHLORIDE HEXAHYDRATE | MANGANESE CHLORIDE TETRAHYDRATE | POTASSIUM IODIDE | SODIUM FLUORIDE | SODIUM MOLYBDATE DIHYDRATE | SODIUM SELENITE ANHYDROUS | ZINC CHLORIDE
Last updated on 9 October 2026
Product Info
ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION
[SIN15302P]
Product information
Active Ingredient and Strength | CHROMIC CHLORIDE HEXAHYDRATE - 5.33 MCG/ML |
Dosage Form | INFUSION, SOLUTION CONCENTRATE |
Manufacturer and Country | HP HALDEN PHARMA AS - NORWAY |
Registration Number | SIN15302P |
Licence Holder | FRESENIUS KABI (SINGAPORE) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | B05XA31 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
To meet basal to moderately increased requirements of trace elements in intravenous nutrition.
Dosing
4.2 Posology and method of administration
Posology
Adults: The recommended daily dose of Addaven in adult patients with basal to moderately increased requirements is 10 ml (one ampoule).
In patients with renal or hepatic impairments, or mild cholestasis the dose should be adapted.
Children ≥ 15 kg: 0.1 ml Addaven is given per kg body weight and day.
Method of administration
Addaven must not be given undiluted. Addaven shall be given as an intravenous infusion, diluted in a parenteral nutrition solution/emulsion.
For instructions on dilution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Conditions with total biliary obstruction.
Wilson’s disease, hemochromatosis.
Children less than 15 kg body weight.